The type of drug resistance | Univariable analysis | Multivariable analysis | ||
OR (95% CI) | P value | aOR (95% CI) | P value | |
G1: smoker +non-drinker vs G0: non-smoker +non-drinker | ||||
DR-TB | 1.01 (0.82 to 1.24) | 0.918 | 0.98 (0.80 to 1.21) | 0.875 |
MR-TB | 1.02 (0.80 to 1.32) | 0.857 | 1.02 (0.79 to 1.32) | 0.888 |
MDR-TB | 0.82 (0.52 to 1.31) | 0.411 | 1.09 (0.73 to 1.61) | 0.685 |
PDR-TB | 1.16 (0.79 to 1.70) | 0.453 | 0.80 (0.50 to 1.28) | 0.354 |
INH-related resistance | 1.09 (0.84 to 1.41) | 0.522 | 1.01 (0.78 to 1.31) | 0.933 |
RIF-related resistance | 0.87 (0.59 to 1.28) | 0.469 | 0.85 (0.57 to 1.25) | 0.403 |
SM-related resistance | 0.98 (0.78 to 1.25) | 0.893 | 1.00 (0.78 to 1.27) | 0.983 |
EMB-related resistance | 0.85 (0.45 to 1.58) | 0.602 | 0.72 (0.38 to 1.35) | 0.299 |
MDR1: INH+RIF | 0.70 (0.22 to 2.28) | 0.553 | 0.67 (0.20 to 2.21) | 0.51 |
MDR2: INH+RIF+EMB+SM | 1.16 (0.49 to 2.72) | 0.742 | 0.98 (0.41 to 2.34) | 0.954 |
MDR3: INH+RIF+SM | 0.97 (0.50 to 1.88) | 0.931 | 1.03 (0.52 to 2.01) | 0.941 |
PDR2: INH+SM | 1.29 (0.85 to 1.96) | 0.236 | 1.25 (0.81 to 1.92) | 0.315 |
PDR3: RIF+SM | 0.31 (0.04 to 2.27) | 0.247 | 0.27 (0.04 to 2.00) | 0.199 |
Any INH+SM resistance | 0.99 (0.81 to 1.23) | 0.956 | 0.97 (0.78 to 1.20) | 0.787 |
Pan-susceptible | reference | reference | reference | reference |
G2: non-smoker +drinker vs G0: non-smoker +non-drinker | ||||
DR-TB | 0.83 (0.61 to 1.13) | 0.241 | 0.77 (0.57 to 1.06) | 0.105 |
MR-TB | 0.75 (0.50 to 1.12) | 0.158 | 0.72 (0.48 to 1.08) | 0.110 |
MDR-TB | 1.19 (0.70 to 2.03) | 0.522 | 0.63 (0.31 to 1.30) | 0.216 |
PDR-TB | 0.70 (0.34 to 1.42) | 0.319 | 1.08 (0.63 to 1.85) | 0.783 |
INH-related resistance | 0.89 (0.60 to 1.31) | 0.543 | 0.82 (0.55 to 1.21) | 0.317 |
RIF-related resistance | 0.73 (0.41 to 1.32) | 0.298 | 0.65 (0.36 to 1.17) | 0.150 |
SM-related resistance | 0.89 (0.63 to 1.26) | 0.512 | 0.84 (0.59 to 1.20) | 0.342 |
EMB-related resistance | 0.65 (0.24 to 1.78) | 0.402 | 0.58 (0.21 to 1.58) | 0.282 |
MDR1: INH+RIF | 0.50 (0.07 to 3.62) | 0.488 | 0.47 (0.06 to 3.48) | 0.460 |
MDR2: INH+RIF+EMB+SM | 1.23 (0.38 to 3.97) | 0.734 | 1.10 (0.33 to 3.62) | 0.876 |
MDR3: INH+RIF+SM | 0.62 (0.19 to 1.96) | 0.410 | 0.54 (0.17 to 1.71) | 0.293 |
PDR2: INH+SM | 1.48 (0.85 to 2.59) | 0.166 | 1.42 (0.81 to 2.49) | 0.227 |
PDR3: RIF+SM | 0.65 (0.09 to 4.83) | 0.678 | 0.48 (0.06 to 3.57) | 0.470 |
Any INH+SM resistance | 0.80 (0.58 to 1.10) | 0.174 | 0.75 (0.54 to 1.04) | 0.082 |
Pan-susceptible | reference | reference | reference | reference |
G3: smoker +drinker vs G0: non-smoker +non-drinker | ||||
DR-TB | 0.89 (0.76 to 1.04) | 0.143 | 0.84 (0.71 to 0.99) | 0.035* |
MR-TB | 0.97 (0.80 to 1.17) | 0.726 | 0.94 (0.77 to 1.14) | 0.508 |
MDR-TB | 0.80 (0.57 to 1.14) | 0.217 | 0.74 (0.53 to 1.04) | 0.078 |
PDR-TB | 0.81 (0.59 to 1.13) | 0.216 | 0.77 (0.54 to 1.10) | 0.149 |
INH-related resistance | 0.89 (0.72 to 1.09) | 0.253 | 0.82 (0.66 to 1.01) | 0.06 |
RIF-related resistance | 0.72 (0.53 to 0.98) | 0.035* | 0.68 (0.49 to 0.93) | 0.015* |
SM-related resistance | 0.84 (0.69 to 1.01) | 0.057 | 0.82 (0.68 to 0.99) | 0.042* |
EMB-related resistance | 0.69 (0.42 to 1.14) | 0.152 | 0.57 (0.34 to 0.95) | 0.032* |
MDR1: INH+RIF | 2.01 (1.13 to 3.57) | 0.018* | 1.91 (1.04 to 3.53) | 0.038* |
MDR2: INH+RIF+EMB+SM | 0.48 (0.19 to 1.21) | 0.12 | 0.40 (0.16 to 1.03) | 0.058 |
MDR3: INH+RIF+SM | 0.39 (0.18 to 0.80) | 0.01* | 0.41 (0.19 to 0.85) | 0.017* |
PDR2: INH+SM | 1.01 (0.72 to 1.43) | 0.951 | 0.94 (0.66 to 1.35) | 0.753 |
PDR3: RIF+SM | 0.31 (0.07 to 1.30) | 0.109 | 0.28 (0.07 to 1.21) | 0.089 |
Any INH+SM resistance | 0.89 (0.75 to 1.04) | 0.142 | 0.85 (0.71 to 1.00) | 0.05* |
Pan-susceptible | reference | reference | reference | reference |
*p<0.05.
aOR, adjusted OR; DR-TB, drug-resistant TB; EMB, ethambutol; INH, isoniazid; MDR-TB, multidrug resistant TB; MR-TB, mono-resistant TB; PDR-TB, polydrug resistant TB; RIF, rifampin; SM, streptomycin; TB, tuberculosis.